AB Corporate Bond ETF (NASDAQ:EYEG) Stock Price Crosses Below 200 Day Moving Average – Should You Sell?

Posted by George Bondi on Jul 23rd, 2026

AB Corporate Bond ETF (NASDAQ:EYEG – Get Free Report)’s stock price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $35.43 and traded as low as $34.75. AB Corporate Bond ETF shares last traded at $34.77, with a volume of 60 shares traded.

AB Corporate Bond ETF Price Performance

The company’s 50-day moving average price is $35.10 and its 200-day moving average price is $35.42. The company has a quick ratio of 3.07, a current ratio of 3.07 and a debt-to-equity ratio of 0.01. The firm has a market cap of $27.61 million, a price-to-earnings ratio of -20.54 and a beta of 0.17.

AB Corporate Bond ETF Cuts Dividend

The firm also recently declared a monthly dividend, which was paid on Tuesday, July 7th. Shareholders of record on Wednesday, July 1st were given a $0.1358 dividend. This represents a c) annualized dividend and a yield of 4.7%. The ex-dividend date of this dividend was Wednesday, July 1st. AB Corporate Bond ETF’s dividend payout ratio (DPR) is currently -102.98%.

Hedge Funds Weigh In On AB Corporate Bond ETF

Institutional investors have recently modified their holdings of the business. Jane Street Group LLC raised its stake in shares of AB Corporate Bond ETF by 166.7% in the fourth quarter. Jane Street Group LLC now owns 15,741 shares of the specialty pharmaceutical company’s stock valued at $563,000 after acquiring an additional 9,839 shares in the last quarter. Kestra Advisory Services LLC acquired a new position in AB Corporate Bond ETF during the 4th quarter worth $34,000. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in AB Corporate Bond ETF by 32.5% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 157,702 shares of the specialty pharmaceutical company’s stock worth $5,634,000 after purchasing an additional 38,685 shares during the period. Institutional investors and hedge funds own 64.16% of the company’s stock.

About AB Corporate Bond ETF

(Get Free Report)

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.